ICU Medical (NASDAQ:ICUI) Issues FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 8.600-9.000 for the period, compared to the consensus estimate of 7.830. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. BTIG Research began coverage on shares of ICU Medical in a research report on Monday, June 15th. They issued a “buy” rating and a $170.00 price target for the company. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. Finally, KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $172.00.

ICU Medical Stock Performance

ICU Medical stock opened at $166.37 on Friday. The stock has a 50-day simple moving average of $150.66 and a 200 day simple moving average of $140.72. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of 89.93, a P/E/G ratio of 2.32 and a beta of 0.74. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical has a 12-month low of $107.00 and a 12-month high of $176.27.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period last year, the company posted $2.10 EPS. ICU Medical’s revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts anticipate that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.10% of the company’s stock.

Trending Headlines about ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations. ICU Medical reported adjusted EPS of $2.37, well above the $1.91 analyst consensus and up from $2.10 a year earlier. Revenue reached $547.9 million versus expectations of $533.4 million. ICU Medical Second-Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised or reaffirmed above Wall Street expectations. ICU Medical provided fiscal 2026 EPS guidance of $8.60 to $9.00, compared with the consensus estimate of $7.83. The guidance signals stronger anticipated earnings than analysts had previously modeled. Analysts Boost ICU Medical Forecasts
• Positive Sentiment: Analysts increased their price targets. Following the earnings beat and updated outlook, analysts raised their forecasts for ICUI, providing an additional catalyst for the stock and indicating improved confidence in the company’s earnings trajectory. Analyst Price-Target Changes
• Neutral Sentiment: Revenue growth remained limited. Quarterly revenue increased only 0.5% year over year, while the company reported a 2.15% net margin and 7.50% return on equity. Investors may therefore focus on whether earnings growth is sustainable and supported by stronger sales expansion. ICU Medical Q2 Key Metrics
• Negative Sentiment: Valuation remains demanding. With ICUI trading near its 52-week high at roughly 90 times earnings, the stock has limited room for execution disappointments despite the positive earnings news.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC grew its position in shares of ICU Medical by 1,299.9% in the fourth quarter. Corient Private Wealth LLC now owns 56,822 shares of the medical instruments supplier’s stock valued at $8,107,000 after purchasing an additional 52,763 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in ICU Medical by 89.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,815 shares of the medical instruments supplier’s stock worth $687,000 after purchasing an additional 2,280 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in ICU Medical during the 4th quarter worth approximately $634,000. Mackenzie Financial Corp bought a new stake in ICU Medical in the 4th quarter valued at $219,000. Finally, XTX Topco Ltd bought a new stake in ICU Medical in the 4th quarter valued at $511,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.